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Abstract 
 
 Purpose: To investigate whether intensity-modulated proton therapy with a reduced 
spot size (rsIMPT) could further reduce the parotid and submandibular gland dose 
compared with previously calculated IMPT plans with a larger spot size. In addition, it was 
investigated if the obtained dose reductions would theoretically translate into a reduction of 
normal tissue complication probabilities (NTCPs). 
 Materials and Methods: Ten patients with N0 oropharyngeal cancer were included in a 
comparative treatment planning study. Both IMPT plans delivered simultaneously 70 Gy to 
the boost planning target volume (PTV) and 54 Gy to the elective nodal PTV.  IMPT and 
rsIMPT used identical 3-field beam arrangements. In the IMPT plans the parotid and 
submandibular salivary glands were spared as much as possible. rsIMPT plans used identical 
dose-volume objectives for the parotid glands as those used by the IMPT plans, whereas the 
objectives for the submandibular glands were tightened further. NTCPs were calculated for 
salivary dysfunction and xerostomia.  
 Result: Target coverage was similar for both IMPT techniques, whereas rsIMPT clearly 
improved target conformity. The mean doses in the parotid glands and submandibular 
glands were significantly lower for three-field rsIMPT (14.7 Gy and 46.9 Gy, respectively) 
than for 3-field IMPT (16.8 Gy and 54.6 Gy, respectively). Hence, rsIMPT significantly 
reduced the NTCP of patient-rated xerostomia and parotid and contralateral submandibular 
salivary flow dysfunction (27%, 17% and 43% respectively) compared with IMPT (39%, 20% 
and 79%, respectively). In addition, mean dose values in the sublingual glands, the soft 
palate and oral cavity were also decreased. Obtained dose and NTCP reductions varied per 
patient. 
 Conclusion: rsIMPT improved sparing of the salivary glands and reduced NTCP for 
xerostomia and parotid and submandibular salivary dysfunction, while maintaining similar 
target coverage results. It is expected that rsIMPT improves quality of life during and after 
radiotherapy treatment. 
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Introduction 
 
In a previous publication, we showed that scanned intensity-modulated proton 
therapy (IMPT) improved organ at risk (OAR)-sparing in advanced oropharyngeal 
cancer cases as compared with an advanced photon technique, i.e. intensity-
modulated radiotherapy (IMRT) [181].  This study showed that 3-field IMPT 
yielded similar results as 7-field IMRT with regard to target coverage, while 3-field 
IMPT significantly reduced the dose to the parotid glands, which is in agreement 
with the results reported by other studies [172,192].  
Of note is that, patient-rated xerostomia, which is the most frequently 
reported radiation-induced side effect significantly affecting quality of life of head 
and neck cancer patients [87], does not only depend on the parotid gland dose, but 
also on the submandibular gland dose [86]. In addition, Murdoch-Kinch et al. [128] 
reported that preservation of the submandibular gland function depends on the 
mean dose to this gland. More specifically, when the mean dose remained below 39 
Gy stimulated and unstimulated flow rates recovered over time, while after a mean 
dose beyond 39 Gy flow rates decreased over time. Unfortunately, 3-field IMPT, as 
reported in our previous study [181], did not reduce the submandibular gland dose 
in the majority of patients. Moreover, most treatment planning comparison studies 
that investigated the potential benefits of protons versus photons in head and neck 
cancer, only took into account the dose distribution in the parotid glands 
[170,172,192]. 
These results indicate that there is still room for further improvement of the 
IMPT plans with regard to salivary gland sparing. It should be emphasized that in 
our previous study [181], a relatively wide proton pencil beam (lateral width) was 
assumed with an initial σ of 3.5 mm in air (σx = σy, full-width-at-half-maximum, 
FWHM, of the Gaussian proton pencil beam is 2.35  σ) which was degraded by 
range shifter plates, the gap to the patients surface, and the patient’s tissue itself 








Figure 1. Sketch of the differences in beam-broadening elements between the Gantry 1 and Gantry 2 
beam line. 
 
In general, the lateral pencil beam width depends on the initial beam width 
(initial phase space) in air and broadening due to multiple Coloumb scattering in 
traversed materials/tissues [141]. Potential benefits of a smaller proton pencil 
beam spot size (lateral width, σ, at the Bragg peak) in head and neck cancer 
treatment was already investigated by Steneker et al. [170] who showed that 
parotid gland sparing could be improved, while maintaining target homogeneity. 
However, in this study, the high risk area did not receive a boost dose which is very 
unlikely to happen in real clinical practice (both the elective nodal areas and the 
high risk area received 54 Gy). Furthermore, the possible sparing of the 
submandibular glands was not investigated. 
Therefore, the aim of the current treatment planning study was to investigate 
whether 3-field IMPT with a reduced spot size (3-field reduced spot IMPT, rsIMPT) 
allows for a further reduction of the dose to the salivary glands compared with 3-
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field IMPT using a larger σ [181] among the same set of oropharyngeal cancer 
cases. In addition, existing normal tissue complication probability (NTCP) models 
were used to investigate if dose reductions obtained with rsIMPT theoretically 
translate into a reduction of salivary flow dysfunction and xerostomia.  
 
Materials and Methods 
 
Patients and computed tomography 
The study cohort consists of ten patients with clinically N0 oropharyngeal 
squamous cell carcinoma with various T-stages (T2-T4N0) [181], previously treated 
with three-dimensional conformal radiotherapy. Planning computed tomography 
(CT) scans were made with patients in supine position. The scanned area extended 
at least 4 cm beyond the planning target volumes (PTVs) in both directions. Slice 
separations were 4 or 5 mm. Target volume and organ at risk (OAR) delineation 
were carried out at the department of Radiation Oncology of the University Medical 
Center Groningen. 
 
Target volumes and OARs 
Target volumes were defined on the planning CT scan by an experienced 
radiation oncologist (H.B.) as described in our previous paper [181]. Two planning 
target volumes, PTV1 and PTV2, were generated. PTV1 enclosed the elective nodal 
areas on both sides of the neck (levels II-IV) and the primary tumour, while PTV2 
only enclosed the primary tumour. The mean volumes of PTV1 and PTV2 were 506 
cm3 (range: 354-658 cm3) and 164 cm3 (range: 25-353 cm3), respectively.  
The delineated OARs included the parotid, submandibular and sublingual 
salivary glands, the soft palate, the oral cavity and the spinal cord. In order to 
ensure consistent delineation, all OARs were delineated according to CT-based 
delineation guidelines for OARs in the head and neck region developed at our 
department (partly presented in [180]).  
For each patient, the same delineated volumes were used to optimize both 
IMPT plans. 
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Treatment planning and the dose delivery model 
IMPT planning was performed on a treatment planning system (TPS) 
developed at  the Paul Scherrer Institute (PSI) for parallel-scanned proton therapy 
[66,116,143,181]. For both the IMPT and rsIMPT plans, the prescribed total dose to 
PTV1 and PTV2 was 54 Gy and 70 Gy, using 1.54 Gy and 2 Gy per fraction in 35 
fractions, respectively, using a simultaneous integrated boost (SIB). This 
fractionation schedule is the current clinical practice for head and neck cancer 
patients treated with photon IMRT at the department of Radiation Oncology of the 
UMCG. A relative biological effectiveness (RBE) of 1.1 relative to 60Co was used for 
the dose calculations.  
For the IMPT plans, delivery characteristics similar to those used in our 
previous publication [181] have been used. That is, that the Bragg peak range is 
modulated by a set of range shifter plates inserted immediately at the exit of the 
nozzle. This has the consequence that the shape of the Bragg peak in depth is 
invariant with energy, but also that the beam in air after the range shifters 
broadens considerably (see Figure 1, left hand diagram).  
For modelling the rsIMPT plans, we have in contrast assumed that energy 
changes will be performed upstream of the treatment gantry, as shown in the 
diagrams on the right hand side of Figure 1. This is the configuration that we have 
on the new PSI gantry currently under development, and is the configuration of all 
commercially available scanning proton systems. This means that, after collimating 
the beam directly after the degradation step, a narrow pencil beam can be 
preserved over a wide energy range, but also has the consequence that the width of 
the Bragg peak in the depth direction will vary with energy. As the TPS used for this 
work has been specifically designed to support the PSI gantry 1, where energy 
variation is achieved through the insertion of range shifter plates at the nozzle exit 
[66,116,181], two simplifications had to be made in order to model such a system.  
The first, and most relevant for this work, is that we had to model the beam 
width in air as being invariant as a function of energy. Although this is not strictly 
correct, the constant value of 3.5 mm sigma we have used in this work is a good 
average value based on measured values for the new gantry, where the beam size in 
IMPT with a reduced spot size potentially improves salivary gland sparing 
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air has been measured to vary from 2.5 mm sigma for 240 MeV to 4.5 mm for 70 
MeV beams. Thus, with a constant value of 3.5 mm we are somewhat 
overestimating the beam width in air for energies above about 110 MeV (equivalent 
to a range of about 10 cm in water) and slightly underestimating beam widths for 
energies below 110 MeV.   
The second, and we believe less relevant simplification for this work, is that 
the Bragg peak shape and width are also invariant with delivered proton energy. 
Although physically not correct, we believe that for the purposes of this paper, this 
is sufficient for the following reasons: 1. We are primarily interested in the quality 
of plans that will be achievable if laterally narrower pencil beams can be delivered. 
As such, the shape of the Bragg peak in depth will have little influence on this. 2. 
The modelling of the beams using a fixed Bragg peak derived from the maximum 
energy required for a field gives a worse case approximation of the distal fall-off, as 
it always models the broadest Bragg peak in depth. Therefore, any benefits we see 
from the use of narrower pencil beams is solely from the lateral width of the pencil 
beams, and not due to the delivery of potentially narrower Bragg peaks.  
Finally for the rsIMPT plans, we have also assumed that a single preabsorber 
can automatically be inserted into the beam at the nozzle exit to help deliver 
superficial (low energy) Bragg peaks. Pre-absorbers will always be required in 
practice to deliver superficial pencil beams, due to the extreme sharpness of the 
Bragg peak for low energies, and the problem of very low transmitted intensity due 
to the energy degrader and subsequent collimation before the beam enters the 
gantry beam line. In this work, we have assumed that a single pre-absorber of 6 cm 
water equivalent thickness will be automatically placed in the beam for delivering 
all pencil beams of a field with a water equivalent residual range in the patient of 
less than 6 cm. Beam broadening due to multiple Coulomb scattering in this pre-
absorber has been modelled.    
For both IMPT and rsIMPT, individual Bragg peaks were distributed over a 
regular grid covering the target volume with a 5 mm spot separation in the plane 
perpendicular to the field direction, and with a separation in depth of 4.6 mm 
(water equivalent). Only Bragg peaks inside the target volume or within 5 mm 
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distance from the target surface were taken into account for the optimization. A 
dose calculation algorithm was used [159] that included heterogeneity corrections 
[143,158], and allowed simultaneous 3D optimization of inhomogeneous (intensity-
modulated) fields [112].  The dose grid resolution was 555 mm3 or 554 mm3 
(depending on the CT-slice separation). Furthermore, identical beam arrangements 
were used for 3-field IMPT and 3-field rsIMPT with gantry angles of 180º (couch 
angle: 0º or ±10º), -50º to -60º (couch angle: 0º) and 50 to 60º (couch angle: 0º) 
[181]. Couch angles were applied for the 180º beam to avoid grazing the skull base.  
 
Plan optimization 
 IMPT plans. Good coverage of the PTVs (satisfying the dose prescriptions), 
without violating the dose constraint to the spinal cord, had the highest priority. 
With exception of the parotid and submandibular glands (as specified below), for 
both treatment techniques, identical target and OAR dose prescriptions and 
acceptance criteria were used as specified in our previous study [181],. For both 
plans, hotspots, a dose >107% to >15 mm3 or >2% of the volume, of the prescribed 
PTV2 dose in the normal tissue volume (NTV, all scanned non-target tissue), were 
not allowed. For 3-field IMPT, optimization took place in 3 steps, each optimizing 
the dose distribution for one of the planning goals, without deteriorating the results 
obtained in the previous step: 1. The dose to the PTV had to satisfy the planning 
goals as well as possible without exceeding the maximum dose to the spinal cord 
(54 Gy); 2. The mean dose to the parotid glands was reduced as much as possible 
by trial-and-error adjustment of the planning optimization dose-volume objectives 
(DVOs) while maintaining adequate target coverage. To avoid conflicting 
objectives, DVOs were only applied to the part of the gland outside the PTVs; 3. 
Finally, the mean dose to the submandibular glands was reduced as much as 
possible in the same way as described for the parotid glands. In some cases, extra 
maximum DVOs to the entire salivary glands were applied to avoid dose values 
higher than the prescribed target dose. 
 rsIMPT plans. Reduced spot IMPT and IMPT used identical dose acceptance 
criteria and dose prescriptions for the PTVs and myelum [181]. More specifically, 
IMPT with a reduced spot size potentially improves salivary gland sparing 
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for the purpose of this study, rsIMPT plans used the same DVOs for the PTVs, 
myelum and parotid glands as used for the IMPT plans. Only the submandibular 
gland DVOs were tightened in order to investigate whether rsIMPT allowed a 
further reduced submandibular gland dose without compromising target coverage.  
 
Evaluation tools 
Dose distributions were evaluated by using dose-volume histograms (DVHs) 
and by checking the presence of hotspots. Plans were compared by using the 
acceptance criteria as specified in our previous paper for the PTVs and spinal cord 
[181]. Additionally, the conformity index (CI) ([volume ≥95% PTV1 dose]/[PTV1]) 
and heterogeneity index (HI) ([D5% - D95%]/Dmean, with Dx% and Dmean being the 
dose level at which the cumulative PTV DVH intersects with x% of volume and the 
mean PTV dose, respectively) were calculated. 
Observed differences between the techniques were tested for statistical 
significance (p < 0.05) using the Wilcoxon signed rank test, for paired data, that 
takes into account the magnitude of the differences and assumes the differences 
come from a symmetric population. All tests were two-tailed. 
 
NTCP models 
We used three existing NTCP models to estimate the clinical relevance of the 
differences in dose distributions among the two IMPT techniques. The first model 
predicts the probability of a reduction in parotid salivary flow below 25% 
referenced to the baseline at ≤6 months after radiotherapy [164]. The input 
parameter in this model is the mean dose to both parotid glands. The second model 
predicts the probability of moderate to severe patient-rated xerostomia at 6 months 
after radiotherapy [86] based on the mean dose to both parotid glands and both 
submandibular glands. The third model predicts the probability of a reduction in 
stimulated submandibular salivary flow per gland below 25% referenced to the 




 - 104 - 
Results 
 
Target volume coverage 
The IMPT and rsIMPT dose distributions satisfied the PTV coverage 
acceptance criteria [181] in all cases (Table 1). Target inhomogeneity was similar for 
both IMPT techniques, whereas rsIMPT clearly improved target conformity (Table 
1 and Figure 2). 
 
Table 1. Planning target volume coverage. 
IMPT rsIMPT
% PTV1 receiving ≥ 95% prescribed dose 98.1 (97.9–98.9) 98.1 (97.9–99.0)
% PTV2 receiving ≥ 95% prescribed dose 98.4 (98.0–99.3) 98.5 (98.0–99.9)
Conformity Index 1.40 (1.32–1.48) 1.23 (1.13–1.41)
Inhomogeneity index PTV1 0.26 (0.22–0.28) 0.25 (0.21–0.28)
Inhomogeneity index PTV2 0.07 (0.06–0.09) 0.06 (0.05–0.07)




 Abbreviations: IMPT, intensity-modulated proton therapy; PTV, planning target volume; rsIMPT, 
reduced spot IMPT. 
 
Normal tissue and OAR-sparing 
The plan acceptance criteria with regard to hotspots and the spinal cord dose 
were satisfied in all cases for both IMPT techniques. Table 2 and Figure 2 (and 
Figure 3d to a lesser extent) show that sparing of the NTV was most effective with 
rsIMPT.  
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Table 2. Irradiated normal tissue volume. 
Statistical 
significance
Normal tissue volume IMPT rsIMPT p
NTV receiving ≥ 95% PTV1 dose 0.22 (0.04) 0.13 (0.03) < 0.01 *
NTV receiving > 107% of PTV2 
dose (hotspots)
0.00 (0.00) 0.00 (0.00) 1.0
NTV receiving ≥ 60 Gy 0.04 (0.02) 0.01 (0.01) < 0.01 *
NTV receiving ≥ 40 Gy 0.55 (0.09) 0.36 (0.06) < 0.01 *
NTV receiving ≥ 20 Gy 1.25 (0.24) 1.01 (0.18) < 0.01 *
NTV receiving ≥ 10 Gy 2.32 (0.48) 2.08 (0.41) < 0.01 *
NTV mean dose 7.3 (1.4) 6.0 (1.1) < 0.01 *
Mean volume [l] or mean 
dose [Gy] (SD) 
 
 
 Abbreviations: IMPT, intensity-modulated proton therapy; NTV, normal tissue volume; PTV, 
planning target volume; rsIMPT, reduced spot IMPT. 
* Wilcoxon test statistically significant (p<0.05). 
 
rsIMPT yielded significantly lower mean doses to both parotid glands (14.7 Gy, 
range: 9.3-25.2 Gy) and both submandibular glands (46.9 Gy range: 39.9-58.8 Gy) 
compared with IMPT (16.8 Gy, range 10.1-27.8 Gy and 54.6 Gy, range 48.1-63.0 Gy, 
respectively). Although mean dose reductions were significant (Figure 4), the mean 
DVHs of the parotid glands and the ipsilateral submandibular gland were only 
slightly lower with rsIMPT (Figure 3). Nevertheless, the mean DVH of the 
contralateral submandibular gland was clearly improved with rsIMPT (Figure 3b), 
resulting in a substantial mean dose reduction (Figure 4). In addition, although no 
constraints were applied to the sublingual glands, the soft palate and oral cavity, 
the mean dose to these structures were also significantly lower with rsIMPT (Figure 










Figure 2. Dose distribution for both intensity-modulated proton therapy (IMPT) plans in Case 2 for 
two subsequent CT slices. Thick lines indicate the volumes of interest: elective planning target volume, 
PTV1 (white); boost volume PTV2 (black); parotid glands (1); submandibular glands (2); sublingual 
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Figure 3. Cumulative dose-volume histograms averaged over all ten cases for the intensity-modulated 
proton therapy (IMPT; dotted line) and reduced spot IMPT (solid line) plans. NTV, normal tissue 
volume. 
 
Figure 5a clearly shows that the dose reduction obtained with rsIMPT 
compared with IMPT varied between cases. Whereas the mean parotid gland dose 
reductions remained below 5 Gy, the corresponding values for the contralateral 
submandibular glands were always higher than 5 Gy, with a maximum of 23.7 Gy. 
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Figure 4. Reduction in mean dose value obtained by application of reduced spot intensity-modulated 
proton therapy (rsIMPT) compared with IMPT. For each OAR, the results of all ten cases are displayed 
by a box plot. * Wilcoxon signed rank test is statistically significant. Cntr, contralateral; Ipsi,  ipsilateral. 
 
NTCP values 
rsIMPT significantly reduced the NTCP values estimated by the parotid and 
contralateral submandibular salivary flow models and the patient-rated xerostomia 
model (Figures 5 and 6, p < 0.01). The average decrease of the NTCP was 3.1% and 
37% for parotid and contralateral submandibular salivary flow dysfunction, 
respectively, and 11.6 % for patient-rated xerostomia. The NTCP reductions varied 
widely among patients (Figure 5b and c). When an NTCP reduction of 10% is 
defined as clinically relevant, none of the patients in this study cohort would 
benefit from rsIMPT with regard to parotid salivary flow dysfunction. However, 
100% and 70% of the included patients would benefit from rsIMPT with regard to 
contralateral submandibular salivary dysfunction and patient-rated xerostomia, 
respectively. 
 
IMPT with a reduced spot size potentially improves salivary gland sparing 
 - 109 - 
 
Figure 5. (a) Differences in mean dose (Dmean) for the submandibular and parotid glands and (b) and 
(c) differences in normal tissue complication probability (NTCP) obtained between 3-field IMPT and 




 With this planning comparative study we showed that rsIMPT significantly 
reduced the mean dose to the major salivary glands, the oral cavity and the soft 
palate, compared with IMPT with a larger spot size, while maintaining adequate 
target coverage, yielding a potential clinical benefit. Hence, these results could 
theoretically lead to relevant clinical benefits with regard to parotid and 
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 There are two important issues that should be taken into account while 
evaluating these results. First, we did not focus on further tightening of the parotid 
gland DVOs with rsIMPT, and effort was only made to improve submandibular 
gland sparing by tightening only those DVOs. The reason for this is that the dose to 
both parotid glands was already low with IMPT (except for one case the mean dose 
to both glands was always far below 26 Gy, range: 10.1–27.8 Gy), whereas the mean 
dose to both submandibular glands was still high (range 48.1–63.0 Gy) [181], and it 
is known that significant dose-effect relationships exist between the submandibular 
gland dose and salivary flow dysfunction and patient-rated xerostomia [86,128]. 
Nonetheless, a smaller spot size automatically improved target dose conformity 
and, therefore, parotid gland sparing. This effect also caused significant dose 
reductions in the sublingual glands, the oral cavity and the soft palate (OARs to 
which no dose constraints were applied). However, to investigate whether rsIMPT 
can further reduce the dose in the parotid glands, the parotid gland DVOs have to 
be tightened as well. Consequently, there may still be room for improvement with 
regard to parotid gland sparing. Second, only the contralateral submandibular 
gland dose reductions lead to a clinically relevant reduction in predicted salivary 
flow dysfunction. For the ipsilateral submandibular gland, at least similar or 
reduced NTCP values were expected with rsIMPT as compared with IMPT (Figure 
4c). This can be explained by the fact that compared with the contralateral gland, 
the ipsilateral gland always overlapped more with the PTVs. Hence, reducing the 
dose in this gland was more difficult. (Dose reductions were always < 2 Gy when 
the ipsilateral submandibular gland overlapped for more than 87% with the PTVs.) 
 Steneker et al. [170] also showed that a smaller spot size improved sparing of 
the parotid glands while maintaining target homogeneity in head and neck cancer 
patients. However, only the low dose PTVs were taken into account, which makes 
this treatment not the state of the art. Additionally, submandibular gland sparing 
was not considered.  
 In a previous planning study, we showed that IMPT (identical to the 3-field 
IMPT plans used in this study) did not allow for a significant submandibular gland 
dose reduction, compared with photon IMRT [181]. Dose reductions for the 
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contralateral and ipsilateral gland were 2.5 Gy (range: -4.4 to 9.9 Gy) and -1.8 Gy 
(range: -6.4 to 1.0 Gy), respectively. The current study, however, shows that 
compared with IMRT, rsIMPT does allow for a substantial contralateral 
submandibular gland dose reduction (mean: 16.6 Gy, range: 6.6 to 22.9 Gy) and, on 
average, a similar ipsilateral gland dose (mean reduction: 0.2 Gy, range: -4.0 to 5.7 
Gy). Additionally, with IMRT in only 20% of the cases the contralateral 
submandibular gland dose could be reduced below 39 Gy, whereas this percentage 
was 30% with IMPT and 80% with rsIMPT.  
 Other studies investigated the feasibility of submandibular gland sparing with 
IMRT [91,155] and reported that it reduced the probability of xerostomia. These 
studies achieved submandibular gland sparing by compromising the target 
coverage [155] or by surgical transfer of the submandibular gland [91]. The current 
study shows that rsIMPT, in contrast to IMRT, allows for a substantial 
contralateral submandibular gland dose reduction without surgical transfer of the 
gland or by compromising target coverage.  
 In general, compared with photons, the penumbra of protons is narrower up 
to a certain penetration depth, i.e. about 17–18 cm (depending on the used proton 
energy) [85]. Goitein reported that great care should be taken to optimize the 
proton penumbrae and that beam sizes should be at the most 10 mm FWHM in air 
at isocenter [69]. During the last decade, in addition to the gantry available at PSI, 
multiple proton therapy facilities allowing for gantry-based scanned proton 
therapy, have been developed or are under construction [142]. However, producing 
small proton beams remains a challenge. With the current gantry at PSI ~8 mm 
FWHM in air can be achieved [116], but this is without the effect of the range 
shifter plates used to modulate energy and which degrade the beam size 
considerably. As previously discussed, with the second generation gantry at least 
similar spot sizes in air and improved spot sizes in the patient can be achieved, 
yielding clinical benefits. 
 It is possible that application of a smaller proton beam spot size (more steep 
dose gradients) results in IMPT plans that are more sensitive to range and dose 
calculation uncertainties, thus decreasing plan robustness [113]. However, whether 
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this effect occurs depends on the exact location of the steep dose gradients within 
the patient. Lomax et al. [113] suggested that the application of fields containing 
mixed spot sizes, with larger spots in the field center and smaller spots at the edges 
(where the glands are located in our case), could minimize this possible effect. 
However, it was beyond the scope of this study to analyze the differences between 




 IMPT applied with a smaller spot size results in a significant reduction of the 
mean parotid and submandibular gland doses. According to NTCP models for 
parotid and submandibular salivary flow dysfunction and patient-rated xerostomia, 
these dose reductions result in significant clinical benefits in most of the cases. 
Therefore, expected is that rsIMPT improves quality of life during and after 
radiotherapy treatment. Further clinical validation is needed to confirm these 
outcomes. 
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